Hepatitis B virus antiviral drug resistance: From the laboratory to the patient

Antiviral Therapy

Volumn 3, Issue 4, 1998, Pages 243-246

  Mutimer, David ^a  

^a QUEEN ELIZABETH HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; LAMIVUDINE; NUCLEOSIDE ANALOG; NUCLEOTIDE DERIVATIVE;

BIOCHEMISTRY; CONFERENCE PAPER; DRUG WITHDRAWAL; GENE MUTATION; HEPATITIS B; HISTOLOGY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIVER CELL; LYMPHOCYTE; PRIORITY JOURNAL; STRUCTURAL GENE; TURNOVER TIME; VIRUS LOAD; VIRUS REPLICATION;

ANTIVIRAL AGENTS; DRUG RESISTANCE; DRUG THERAPY, COMBINATION; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; LAMIVUDINE;

EID: 0032443586     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (13)

1. Nowak MA, Bonhoeffer S, Hill AM, Boehme R, Thomas HC & McDade H. Viral dynamics in hepatitis B virus infection. Proceedings of the National Academy of Sciences, USA 1996; 93:4398-4402.
2. Zeuzem S, de Man RA, Honkoop P, Schalm SW & Schmidt JM. Dynamics of hepatitis B virus infection in vivo. Journal of Hepatology 1997; 27:431-436.
3. Wong DK, Cheung AM, O'Rourke K, Naylor CD, Detsky AS & Heathcote J. Effect of alpha-interferon treatment in patients with hepatitis B e antigen positive chronic hepatitis B: a meta-analysis. Annals of Internal Medicine 1993; 119:312-323.
4. Perrillo RP, Schiff ER, Davis GL, Bodenheimer Jr HC, Lindsay K, Payne J, Dienstag JL, O'Brien C, Tamburro C, Jacobson IM, Sampliner R, Feit D, Lefkowitch J, Kuhns M, Meschievitz C, Sanghvi B, Albrecht J & Gibas A. A randomised, controlled trial of Interferon alpha-2b alone and after prednisolone withdrawal for the treatment of chronic hepatitis B. New England Journal of Medicine 1990; 323:295-301.
5. Brook MG, Karayiannis P & Thomas HC. Which patients with chronic hepatitis B virus infection will respond to alpha-interferon therapy? A statistical analysis of risk factors. Hepatology 1989; 10:761-763.
6. Dienstag JL, Perrillo RP, Schiff ER, Bartholomew M, Vicary C & Rubin M. A preliminary trial of lamivudine for chronic hepatitis B infection. New England Journal of Medicine 1995; 333:1657-1661.
7. Grellier L, Mutimer DJ, Ahmed M, Brown D, Burroughs AK, Rolles K, McMaster P, Beranek P, Kennedy F, Kibbler H, McPhillips P, Elias E & Dusheiko G. Lamivudine prophylaxis: a new strategy for prevention of reinfection in liver transplantation for hepatitis B cirrhosis. Lancet 1996; 348;1212-1215.
8. Nevens F, Main J, Honkoop P, Tyrrell DL, Barber J, Sullivan MT, Fevery J, de Man RA & Thomas HC. Lamivudine therapy for chronic hepatitis B: a six-month dose-ranging study. Gastroenterology 1997; 113:1258-1263.
9. Lai CL, Liaw YF, Leung NWY, Chang TT, Guan R, Tai DI, Ng KY, Wu PC, Dent JC & Gray DF. 12 months of lamivudine therapy improves liver histology: results of a placebo-controlled multicentre study in Asia. Journal of Hepatology 1997; 26 (Suppl. 1):79.
10. Heathcote J, Schalm SW, Cianciara J, Farrell G, Feinmann V, Shermann M, Dhillon AP, Moorat AE & Gray DF. Lamivudine and Intron A combination treatment in patients with chronic hepatitis B infection. Journal of Hcpatology 1998; 28:43.
11. Ling R, Mutimer DJ, Ahmed M, Boxall EH, Elias E, Dusheiko GM & Harrison TJ. Selection of mutations in the hepatitis B virus polymerase during therapy of transplant recipients with lamivudine. Hepatology 1996; 24:711-713.
12. Tipples GA, Ma MM, Fischer KP, Bain VG, Kneteman NM & Tyrrell DLJ. Mutation in HBV-dependent DNA polymerase confers resistance to lamivudine in vivo. Hepatohgy 1996; 24:714-717.
13. Bartholomew MM, Jansen RW, Jeffers LJ, Reddy KR, Johnson LC, Bunzendahl H, Condreay LD, Tzakis AG, Schiff ER & Brown NA. Hepatitis-B-virus resistance to lamivudine given for recurrent infection after liver transplantation. Lancet 1997; 349:20-22.